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Abstract
Introduction Obesity has been linked to increased risk of breast
cancer in postmenopausal women. Increased peripheral
production of estrogens has been regarded as the main cause
for this association, but other features of increased body fat
mass may also play a part. Leptin is a protein produced mainly
by adipose tissue and may represent a growth factor in cancer.
We examined the association between leptin plasma levels and
mammographic density, a biomarker for breast cancer risk.
Methods We included data from postmenopausal women aged
55 and older, who participated in a cross-sectional
mammography study in Tromsø, Norway. Mammograms, plasma
leptin measurements as well as information on anthropometric
and hormonal/reproductive factors were available from 967
women. We assessed mammographic density using a
previously validated computer-assisted method. Multiple linear
regression analysis was applied to investigate the association
between mammographic density and quartiles of plasma leptin
concentration. Because we hypothesized that the effect of leptin
on mammographic density could vary depending on the amount
of nondense or fat tissue in the breast, we also performed
analyses on plasma leptin levels and mammographic density
within tertiles of mammographic nondense area.
Results After adjusting for age, postmenopausal hormone use,
number of full-term pregnancies and age of first birth, there was
an inverse association between leptin and absolute
mammographic density (Ptrend = 0.001). When we additionally
adjusted for body mass index and mammographic nondense
area, no statistically significant association between plasma
leptin and mammographic density was found (Ptrend = 0.16).
Stratified analyses suggested that the association between
plasma leptin and mammographic density could differ with the
amount of nondense area of the mammogram, with the
strongest association between leptin and mammographic
absolute density in the stratum with the medium breast fat
content (Ptrend = 0.003, P for interaction = 0.05).
Conclusion We found no overall consistent association
between the plasma concentration of leptin and absolute
mammographic density. Although weak, there was some
suggestion that the association between leptin and
mammographic density could differ with the amount of fat tissue
in the breast.
Introduction
Obesity has been associated with increased risk of postmen-
opausal breast cancer in epidemiological studies [1-3]. The
increased conversion of androgens to estrogens by the aro-
matase enzyme in peripheral adipose tissues [4] along with
reduced levels of serum sex hormone binding globulin have
been hypothesized to be the main link between obesity and
increased risk of postmenopausal breast cancer [2].
Whether the influence of estrogens on the breast tissue is
direct or is mediated via other factors, however, has not been
established [5]. In addition to being the main site for
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production of postmenopausal estrogens, adipocytes secrete
a number of biological active polypeptides, the adipocytokines
[6], some of which may be involved in breast cancer develop-
ment [7].
Leptin, the most thoroughly studied adipocytokine, is a protein
hormone produced mainly by the white adipose tissue [8,9],
but is also expressed at other sites, such as in the gastric epi-
thelium [10], the placenta [11], osteoblasts [12], skeletal mus-
cle cells [13] and mammary epithelium [14]. Leptin regulates
appetite and energy expenditure by signaling nutritional status
to the hypothalamus [15], but is also involved in a number of
other processes including the regulation of reproduction and
immune response [16,17].
Leptin may act as a growth factor in cancer [18], including the
epithelial cancers of colon and breast [19]. Leptin promotes
angiogenesis [20-22] and might thereby directly stimulate
growth of breast cancer cells [23].
The radiographic appearance of a mammogram is determined
by the relative amounts of translucent fat tissue to the denser
epithelial and stromal (fibrous) tissues [24]. Mammographic
density is a measure of the radiodense area on the mammo-
gram. Both the amount of radiodense tissue (absolute mam-
mographic density) and the percentage of total breast area
that appears radiologically dense (percentage mammographic
density) have been shown to be associated with breast cancer
risk; women with the most dense mammograms having a four
to six times higher risk of developing breast cancer compared
with women with no densities [25-27]. It was recently shown
that ductal carcinoma in situ tumors tend to arise in the area
of the breast corresponding to the dense part of the mammo-
gram [28], and it has been suggested that mammographic
density represents an early biomarker for breast cancer risk
[29].
In the present cross-sectional study, we wanted to examine
the association between plasma leptin concentration and
mammographic density. We hypothesized that the growth-
promoting properties of leptin, by stimulating proliferation of
epithelial tissue and/or stromal tissue of the breast, could
potentially increase the density of the mammogram. As abso-
lute mammographic density is under smaller influence by
breast fat and body fat measures than percentage mammo-
graphic density, we used absolute density as the main mam-
mographic density variable in our analyses.
Materials and methods
Study population
We used data from the Tromsø Mammography and Breast
Cancer Study, which aims to identify genetic, hormonal, repro-
ductive and lifestyle characteristics associated with mammo-
graphic patterns/densities that may enhance the risk of
developing breast cancer [30]. Briefly, women aged 55 and
older, residing in the municipality of Tromsø, who attended the
National Breast Cancer Screening Program at the University
Hospital of North Norway during spring 2001 and 2002, were
invited to participate in the study. A total of 1,041 women
agreed to participate. This accounted for 70.2% of the women
attending the breast cancer screening program during recruit-
ment. Of the 1,041 women, we excluded 22 women with new
or previous breast cancer and one woman currently using
chemotherapy.
A blood sample was drawn and anthropometric measures
were obtained from the participants on the day of the mammo-
graphic screening. The study subjects were interviewed by a
trained nurse about their current and previous postmenopau-
sal hormone therapy use, their reproductive and menstrual fac-
tors, their previous history of cancer and their smoking status.
The participants were asked to complete either a four-page
questionnaire (2001 participants) or an eight-page question-
naire (2002 participants) at home. The questionnaires con-
tained items on demographic, menstrual and reproductive
factors, as well as lifestyle and dietary factors. The study was
approved by the Regional Committee for Medical Research
Ethics and the National Data Inspection Board. All participants
gave written informed consent.
Assay of plasma samples
Nonfasting venous samples were obtained from the partici-
pants on the day of mammographic screening. Samples were
stored at -20°C or colder until analysis in December 2002.
Samples had been thawed once during storage. The plasma
leptin concentration was measured by a competitive radioim-
munoassay (Linco Research, St Charles, MO, USA) with
recombinant 125I-leptin as a tracer [31]. The intra-assay coeffi-
cient of variation was 2.4%, whereas the inter-assay coeffi-
cient of variation was 6.6%. Leptin measurements were
available for 975 women.
Processing of mammograms
Absolute and percentage mammographic densities were
determined using the University of Southern California
Madena computer-based threshold method of assessing den-
sity, a method that has been described and validated else-
where [32]. Briefly, the cranio-caudal mammographic images
are digitized using a high-resolution Cobrascan CX-812 scan-
ner (Radiographic Digital Imaging, Torrance, CA, USA) and
were then viewed on a computer screen. The computer soft-
ware program assigns a pixel value of 0 to the darkest (black)
shade in the image and a value of 255 to the lightest (white)
shade with shades of gray assigned intermediate values.
A reader first defines the total breast area using a special out-
lining tool. Next, the region of interest, excluding the pectoralis
muscle, prominent veins and fibrous strands, is defined. The
reader then uses a tinting tool to apply a yellow tint to dense
pixels with grey levels at or above some threshold X and a pixelAvailable online http://breast-cancer-research.com/content/8/5/R55
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value of 255. The reader searches for the best threshold
where all pixels X within the region of interest are considered
to represent mammographic densities. The software estimates
the total number of pixels and the number of tinted pixels within
the region of interest.
The absolute density represents the count of the tinted pixels
within the region of interest. The percentage density, or the
fraction (%) of the breast with densities, is the ratio of absolute
density to the total breast area. As a measure of breast adi-
pose tissue, we used the mammographic nondense area,
which we estimated as the total breast area minus the abso-
lute density. All measurements were made on the mammo-
gram from the left breast. The density assessments were
performed by GU, whereas the breast area measurements
were conducted by a research assistant trained by GU. The
readers were blinded to all subject characteristics.
Data analysis
In our preliminary analyses, we used analysis of variance to
study the associations between leptin and selected variables,
and the associations between absolute mammographic den-
sity and the same selected variables. We also conducted
these analyses adjusted for body mass index (BMI).
The association between plasma leptin concentration and
mammographic density was studied by multiple linear regres-
sion analysis with mammographic density as the outcome var-
iable. Consistent with our previously reported findings on
percentage mammographic density from this study [30], we
found that absolute mammographic density decreased with
higher BMI, with increasing number of full-term pregnancies
and with lower age at first birth. We adjusted for these varia-
bles in the multivariate analyses, in addition to age, current use
of postmenopausal hormone therapy and mammographic non-
dense area. In the multivariate analyses, leptin was categorized
into quartiles, and the covariates were modeled as categorical
variables with the following categories: BMI (<20, 20–22, 23–
24, 25–26, 27–28, 29–31, 32–34, >34), age (tertiles),
number of full-term pregnancies (0, 1–2, 3, >3), age at first
birth (<20 years, 20–24 years, >24 years), current postmeno-
pausal hormone therapy use (yes/no) and breast fat tissue (ter-
tiles). In the stratified analyses, BMI was categorized as <23,
23–24, 25–26, 27–28, >28.
To meet the assumptions of normality of residuals from the
regression analyses, both the leptin concentration and mam-
mographic density were log10-transformed in the analyses
where they represented the outcome variable. Back-trans-
formed means and 95% confidence intervals are presented.
Test for trends across categories of variables were performed
by treating the categories as continuous variables in the anal-
yses. For the multivariate analyses on leptin concentration and
mammographic density, complete information was available
for 967 women.
Leptin concentration was correlated with the body fat meas-
ures of BMI (Spearman's rank correlation, rsp = 0.56, P  <
0.001), waist circumference (rsp = 0.52, P  < 0.001) and
breast fat tissue (rsp = 0.40, P < 0.001). The body fat meas-
ures of BMI, breast fat tissue and waist circumference were
also correlated (0.66 ≤ rsp ≤ 0.87, with the highest correlation
of 0.87 between BMI and waist circumference). Because we
wanted to investigate the effect of leptin as a possible growth
factor independent of body fat, we performed several analyses
adjusting for BMI, mammographic nondense area (represent-
ing breast fat) and waist circumference one at a time or
together, and with various categorizations of the variables.
In the following, we present results adjusted for BMI and/or
mammographic nondense area. Additional adjustment for
Table 1
Characteristics of women included in the study (n = 967)
Age (years) 60 (55–71)
Body mass index (kg/m2) 26.7 (13.1–47.2)
Number of full-term pregnancies 3 (0–11)
Age at first birth (n = 816) 22 (15–39)
Absolute mammographic density (cm2) 14.7 (0–155.2)
Percentage mammographic density (%) 9.6 (0–69.2)
Leptin (ng/ml) 14.5 (1.0–72.0)
Current postmenopausal hormone therapy use 253 (26)
Smoking (n = 906)
Current daily smoking 268 (30)
Current nonsmoking 638 (70)
Data presented as the median (range) or number of observations (percentage).Breast Cancer Research    Vol 8 No 5    Stuedal et al.
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Table 2
Selected variables in relation to leptin and absolute mammographic densitya
n Leptin concentration 
(ng/ml)
Leptin 
concentration (ng/
ml) adjusted for 
BMIb
P valuec Absolute 
mammographic 
density (cm2)
Absolute 
mammographic 
density (cm2) adjusted 
for BMIb
P valuec
Age in tertiles (n = 967)
55–58 years 318 14.0 (12.9–15.2) 13.4 (12.5–14.4) 13.3 (11.6–15.2) 12.6 (11.0–14.4)
59–63 years 340 14.4 (13.3–15.6) 13.6 (12.7–14.6) 10.9 (9.6–12.4) 10.3 (9.0–11.7)
64–71 years 309 14.1 (13.0–15.3) 13.4 (12.5–14.4) 0.98 10.5 (9.2–12.1) 10.1 (8.8–11.5) 0.01
Number of full-term 
pregnancies (n = 967)
0 69 14.7 (12.4–17.5) 14.9 (12.9–17.2) 19.7 (15.0–26.1) 18.1 (13.9–23.7)
1–2 385 12.9 (12.0–13.8) 12.6 (11.8–13.4) 13.8 (12.3–15.5) 13.0 (11.5–14.7)
3 309 14.6 (13.5–15.9) 14.2 (13.2–15.3) 11.4 (10.0–13.0) 10.6 (9.3–12.19
4 and more 204 15.9 (14.4–17.6) 13.8 (12.6–15.0) 0.30 6.8 (5.8–8.0) 6.8 (5.8–8.0) <0.001
Age at first birth (n = 898) 
(82 have imputed values)
< 20 years 129 16.3 (14.4–18.5) 14.4 (12.9–16.0) 7.2 (5.9–8.9) 7.1 (5.8–8.7)
20–24 years 535 14.1 (13.2–15.0) 13.2 (12.5–14.0) 10.9 (9.9–12.1) 10.2 (9.2–11.4)
>24 years 234 13.1 (12.0–14.4) 12.7 (11.7–14.0) 0.08 14.2 (12.1–16.5) 13.3 (11.4–15.5) <0.001
Postmenopausal hormone 
use (n = 967)
Current use 253 13.5 (12.3–14.8) 13.5 (12.5–14.6) 16.7 (14.4–19.3) 15.1 (13.0–17.6)
Current nonuse 714 14.4 (13.6–15.2) 13.5 (12.8–14.2) 0.97 10.1 (9.2–11.0) 9.8 (8.9–10.7) <0.001
Smoking (n = 906)
Current nonsmoking 638 15.5 (14.7–16.4) 14.1 (13.4–14.8) 11.6 (10.6–12.8) 11.6 (10.5–12.8)
Current daily smoking 268 11.4 (10.4–12.4) 12.4 (11.5–13.4) 0.01 11.2 (9.7–13.0) 9.4 (8.1–10.9) 0.02
Alcohol consumption (100 
g alcohol/month) (n = 
877)
No alcohol 225 14.0 (12.7–15.4) 13.1 (12.1–14.2) 10.4 (8.9–12.2) 10.4 (8.9–12.1)
Lower tertile (<0.42) 206 14.5 (13.1–16.0) 13.8 (13.0–15.1) 10.5 (8.9–12.4) 9.9 (8.4–11.7)
Mid tertile (0.42–1.1) 213 15.1 (13.6–16.6) 13.9 (12.7–15.1) 10.5 (8.9–12.3) 10.2 (8.7–12.1)
Upper tertile (>1.1) 233 13.5 (12.3–14.9) 13.7 (12.6–14.9) 0.48 14.2 (12.2–16.6) 12.7 (10.8–14.8) 0.06
BMI (n = 967)
<25 330 9.0 (8.4–9.6) 16.4 (14.5–18.6)
25–30 393 15.1 (14.2–16.0) 11.8 (10.5–13.3)
>30 244 23.8 (22.0–25.8) <0.001 6.8 (5.8–7.8) <0.001
Waist circumference in 
tertiles (n = 965)
<83.6 cm 323 9.1 (8.5–9.8) 16.3 (14.3–18.5)
83.6–94.1 cm 326 14.4 (13.4–15.4) 12.7 (11.2–14.4)
>94.1 cm 316 21.9 (20.4–23.5) <0.001 7.3 (6.4–8.3) <0.001
Mammographic nondense 
area in tertiles (n = 967)
<120.1 cm2 325 9.8 (9.1–10.6) 12.4 (11.5–13.4) 20.3 (18.0–22.9) 18.2 (15.8–20.9)
120.1–172.8 cm2 319 15.0 (14.0–16.2) 14.1 (13.1–15.2) 12.2 (10.8–13.8) 11.2 (9.8–12.9)
>172.8 cm2 323 19.3 (17.9–20.8) 14.1 (13.1–15.2) 0.03 6.1 (5.4–6.9) 6.4 (5.6–7.5) <0.001Available online http://breast-cancer-research.com/content/8/5/R55
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waist circumference, smoking and alcohol consumption
yielded essentially similar results, and are not presented.
Furthermore, because of the correlation (rsp = 0.56) between
our main independent variable, leptin concentration, and BMI,
we additionally performed our multivariate analyses with leptin
concentration adjusted for BMI by the residual method [33].
We hypothesized that the association between plasma leptin
concentration and absolute mammographic density could be
modified by the amount of fat tissue in the breast. We there-
fore also performed multivariate analyses within tertiles of the
mammographic nondense area.
Of the 967 women in the analyses, 898 reported one or more
full-term pregnancies. For 82 of these women, information on
age at first birth was not available. In order to keep these
women in the adjusted analyses we replaced the missing val-
ues with the median age at first birth for women with the same
age and same number of full-term pregnancies.
From the multiple linear regression model of plasma leptin and
absolute mammographic density, we report R2 values for the
total model and the R2 change values for the plasma leptin
concentration. The statistical analyses were performed using
SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL,
USA). All P values are two-sided. We considered P < 0.05
statistically significant.
Results
The characteristics of the study subjects are summarized in
Table 1. The median absolute mammographic density was
14.7 cm2 (range, 0–155.2 cm2) and the median plasma leptin
concentration was 14.5 ng/ml (range, 1.0–72.0 ng/ml).
Table 2 presents the associations between selected variables
and leptin concentration as well as absolute mammographic
density. After adjustment for BMI, the leptin concentration
decreased statistically nonsignificantly with higher age at first
birth, and smokers had significantly lower plasma leptin levels
than nonsmokers. Moreover, plasma leptin concentration was
positively and statistically significantly associated with BMI,
waist circumference and the nondense area of the mammo-
gram. Absolute mammographic density decreased statistically
significantly with age, with increasing number of full-term preg-
nancies and was lower with an early first birth. Women using
postmenopausal hormone therapy had a significantly higher
absolute mammographic density, on average 5.3 cm2, com-
pared with non-hormone users. Absolute mammographic den-
sity was inversely and statistically significantly associated with
BMI, waist circumference and the nondense area of the
mammogram.
Plasma leptin concentration and mammographic density
Plasma leptin levels and absolute mammographic density
were weakly correlated (rsp = -0.12, P < 0.001), and a statisti-
cally significant inverse association was found in the unad-
justed regression analysis (Table 3). After adjustment for age,
number of full-term pregnancies, age at first birth, use of post-
menopausal hormone therapy, BMI and mammographic non-
dense area, this inverse association was no longer apparent.
The pattern was essentially the same for the percentage mam-
mographic density (Table 3). When we replaced the leptin
concentration with that adjusted for BMI by the residual
method in the multivariate analyses, the association between
leptin concentration and mammographic density remained
essentially unchanged. For the absolute density Ptrend changed
from 0.32 to 0.28, and for the percentage density Ptrend
changed from 0.58 to 0.43 (analyses not adjusted for non-
dense mammographic area) (results not shown).
In analysis stratified by tertiles of mammographic nondense
area, no statistically significant association was found
between the plasma leptin concentration and the absolute
mammographic density in the strata representing the women
with the lowest or the highest breast fat content (Table 4). In
the stratum with the medium nondense area, the absolute
mammographic density increased statistically significantly
across quartiles of leptin. Women in the highest quartile of
plasma leptin concentration had, on average, 9.7 cm2 higher
absolute mammographic density compared with the women in
the lowest quartile (Ptrend = 0.003). This apparent effect mod-
ification was statistically borderline significant (P for interac-
tion = 0.05). Stratified analyses not adjusted for BMI gave
essentially the same results (P for interaction = 0.06). For the
percentage density, the association between leptin
Mammographic 
percentage density in 
tertiles (n = 967)
< 4.5% 322 17.5 (16.2–19.0) 13.4 (12.5–14.4)
4.5–15.5% 322 13.8 (12.7–14.9) 13.6 (12.7–14.6)
>15.5% 323 11.8 (10.9–12.7) 13.5 (12.5–14.5) 0.9
aAnalysis of variance. Leptin and absolute mammographic density were log-transformed, reported means are back-transformed
bAdjusted for body mass index (BMI), categorized as <20, 20–22, 23–24, 25–26, 27–28, 29–31, 32–34, >34.
cFor dichotomous variables, P values were obtained from analysis of variance, otherwise P values were obtained from test for trend. Analyses are 
adjusted for BMI; except for BMI and waist circumference, where the trend tests refer to the crude analyses.
Table 2 (Continued)
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concentration and mammographic density resembled those of
the absolute mammographic density, with an inverse associa-
tion in the lower stratum of nondense mammographic area
(Ptrend = 0.05), a positive association in the medium stratum
(Ptrend = 0.004) and no association in the upper stratum (Ptrend
= 0.76) (results not shown).
We also performed the analysis on leptin concentration and
absolute mammographic density in the strata of the second
tertile and the third tertile of nondense mammographic area
combined. In this new stratum, the absolute density was on
average 3.9 cm2 higher in the highest quartile of plasma leptin
concentration compared with the lowest quartile (Ptrend =
0.12, P for interaction = 0.23) (results not shown). When we
Table 3
Unadjusted and adjusted means of mammographic density (95% confidence interval) in quartiles of plasma leptin concentrationa (n 
= 967)
Quartile of plasma leptin concentration Ptrend
<9.1 ng/ml 9.1–14.5 ng/ml 14.6–24.0 ng/ml >24.0 ng/ml
n 251 234 243 239
Absolute mammographic density (cm2)
Unadjusted 13.8 (11.9–16.0) 13.5 (11.6–15.8) 9.4 (8.1–11.0) 9.9 (8.5–11.5) <0.001
Adjustedb 14.7 (12.4–17.4) 14.9 (12.5–17.6) 10.7 (9.1–12.6) 11.2 (9.5–13.2) 0.001
Adjustedb, additionally adjusted for nondense areac 11.7 (9.9–13.7) 13.3 (11.3–15.7) 11.0 (9.5–12.9) 12.9 (11.1–15.1) 0.70
Adjustedb, additionally adjusted for BMId 11.2 (9.4–13.3) 12.4 (10.4–14.9) 10.4 (8.8–12.3) 13.4 (11.3–15.9) 0.32
Adjustedb, additionally adjusted for nondense areac 
and BMId
10.7 (9.0–12.7) 12.2 (10.2–14.5) 10.4 (8.9–12.3) 13.3 (11.3–15.7) 0.16
Percent mammographic density (%)
Unadjusted 11.3 (9.8–12.9) 9.6 (8.3–11.0) 6.4 (5.5–7.3) 6.2 (5.4–7.2) <0.001
Adjustedb, and additionally adjusted for BMId 8.6 (7.3–10.0) 9.1(7.7–10.6) 7.6 (6.5–8.8) 9.7 (8.3–11.2) 0.58
aMultiple linear regression. The absolute and percentage mammographic densities were log-transformed, reported means are back-transformed.
bAdjusted for age (tertiles), full-term pregnancies (none, 1–2, 3, >3), age at first birth (<20 years, 20–24 years, >24 years) and postmenopausal 
hormone therapy (current use/noncurrent use).
cNondense mammographic area (tertiles).
dBody mass index (BMI), <20, 20–22, 23–24, 25–26, 27–28, 29–31, 32–34, >34.
Table 4
Adjusted means of absolute mammographic densitya (95% confidence interval) in quartiles of plasma leptin concentration, 
stratified by tertiles of nondense mammographic area (n = 967)
Nondense mammographic area Quartile of plasma leptin concentration Ptrend
<9.1 ng/ml 9.1–14.5 ng/ml 14.6–24.0 ng/ml >24.0 ng/ml
First tertile (n) 140 90 55 40
Mammographic density, adjustedb 19.1(16.2–22.6) 17.8 (14.7–21.5) 16.8 (13.5–20.9) 19.4 (15.0–25.2) 0.7
Mammographic density, adjustedb, 
additionally adjusted for BMIc
22.1 (18.2–26.8) 19.0 (15.6–23.1) 17.5 (14.0–21.9) 18.7 (14.4–24.3) 0.12
Second tertile (n) 6 88 29 47 5
Mammographic density, adjustedb 10.6 (7.8–14.5) 14.1(10.4–19.1) 13.2 (10.1–17.4) 17.3 (13.1–22.8) 0.02
Mammographic density, adjustedb, 
additionally adjusted for BMIc
9.9 (7.2–13.6) 14.0 (10.3–19.0) 13.7 (10.3–18.2) 19.6 (14.6–26.3) 0.003
Third tertile (n) 4 36 29 41 2 4
Mammographic density, adjustedb 7.5 (4.9–11.6) 10.4 (7.2–15.0) 6.2 (4.5–8.5) 7.0 (5.2–9.4) 0.22
Mammographic density, adjustedb, 
additionally adjusted for BMIc
8.2 (5.1–13.1) 11.3 (7.7–16.7) 7.5 (5.1–10.9) 8.6 (5.9–12.5) 0.63
aMultiple linear regression. Absolute mammographic density was log-transformed, reported means are back-transformed.
bAdjusted for age (tertiles), full-term pregnancies (none, 1–2, 3, >3), age at first birth (<20 years, 20–24 years, >24 years) and postmenopausal 
hormone therapy (current use/noncurrent use).
cBody mass index (BMI), <23, 23–24, 25–26, 27–28, >28.Available online http://breast-cancer-research.com/content/8/5/R55
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restricted the analysis to women having a BMI between 18
and 40 (n = 945) or to women in the 5th-95th percentiles of
nondense mammographic area (n = 872), or to non-current
hormone therapy users (n = 714), the associations between
leptin concentration and mammographic density were essen-
tially unchanged.
In the adjusted analyses of plasma leptin levels and absolute
mammographic density, with a model where both BMI and
nondense area were included, the R2 value was 22.6% (P <
0.001) and the R2 change value for leptin concentration was
0.6% (P = 0.05).
Discussion
Epidemiological studies on leptin and breast cancer have
been scarce and inconclusive. One small case-control study
found no association between the serum leptin concentration
and breast cancer among postmenopausal women, but found
an inverse association among premenopausal women [34].
Another small case-control study performed among premeno-
pausal women [35] reported a statistically nonsignificant pos-
itive association between serum leptin levels and the risk of
carcinoma in situ of the breast. A Swedish nested case-con-
trol study on postmenopausal women [36] found no statisti-
cally significant association between plasma levels of leptin
and breast cancer risk. One earlier study [37] evaluated the
association between circulating leptin levels among premeno-
pausal women and mammographic density, assessed by the
Wolfe's classification system. In that study, leptin was
inversely associated with high-risk mammographic patterns.
This is in accordance with our analyses not adjusted for body
fat measures.
The present study found a crude inverse association between
leptin concentration and mammographic density. This associ-
ation disappeared after adjustment for body fat measures. The
small R2 change of 0.6% for leptin concentration suggests a
marginal, if any, role for leptin in determining mammographic
density. We did find, however, a statistically significant
increase in mammographic density across quartiles of leptin
concentration among the women with a medium content of
nondense tissue or breast fat.
Because leptin is produced and secreted mainly from the adi-
pose tissue, it may seem inappropriate from a biologic point of
view to separate the association between leptin concentration
and mammographic density from that of the association
between body fat and mammographic density. Furthermore, it
may seem puzzling that fat measures are inversely associated
with mammographic density, whereas tentatively a positive
association could exist between leptin and mammographic
density, as suggested from our stratified analyses adjusted for
fat measures.
Obesity is associated with increased breast cancer risk in
postmenopausal women [1]. Paradoxically, obesity has shown
to be associated with favorable mammographic patterns,
regardless of methods of mammographic assessment [38-
40]. The reason why obesity should be related to a smaller
amount of fibroglandular tissue in the breast is unclear [41]. To
our knowledge it is not known what determines the relative
amounts of fat and stromal tissue during human female breast
development. Interestingly, it is well known from dairy science
that high-energy feeding in heifers (a young cow that has not
had a calf) increases mammary fat deposits and decreases the
number of epithelial cells [42]. It has been suggested that lep-
tin might, via a regulatory effect on DNA synthesis in bovine
mammary epithelial cells, mediate such an effect [43]. Further-
more, even if body fat measures are inversely associated with
mammographic density, there could still be positive associa-
tions between specific fat-related substances [6] and mam-
mographic density. To investigate an association between
leptin and mammographic density, we therefore had to adjust
for the confounding effect of body fat.
Although percentage mammographic density is a more com-
monly used estimate, absolute density has also been associ-
ated with breast cancer [26,27,44,45]. Absolute density may
be a more appropriate marker in studies where body fat mass
is investigated, such as in dietary studies [46-48].
A role for leptin in breast cancer tumorigenesis has been
hypothesized based on the detection of leptin protein in
human breast tumors [49], the detection of leptin receptors
and the proliferative effect of leptin in breast cancer cell lines
[23,50,51]. Lack of oncogene-induced mammary tumors in
genetically obese mice, leptin-deficient (ob/ob) mice [52] or
leptin-receptor-deficient (db/db) mice [53] have also been dis-
cussed in light of this hypothesis. The influence of leptin on
normal breast tissue, however, is less investigated. Leptin
receptors have been detected in the normal human breast epi-
thelial HBL100 cell line [23], whereas investigators failed to
demonstrate any significant immunoreactiviety of the leptin
receptor (OB-R) in normal breast gland [54]. Leptin mRNA
expression has been detected in normal breast tissue and in
secretory breast epithelial cells [14], in benign epithelial hyper-
plasia as well as in normal epithelial cells in the vicinity of
malign lesions [55]. Breast epithelial cells, therefore, might
under certain circumstances themselves produce and/secrete
leptin. Normal breast tissue appears to have lower or absent
leptin expression compared with cells of benign breast lesions
and malignant ductal cells [54,55]. These observations could
indicate a role for leptin during malignant transformation of
breast cells.
Although it is particularly the effect of leptin on epithelial mam-
mary duct cells of the breast that has been studied, leptin
might promote growth in other cell populations of the breast,Breast Cancer Research    Vol 8 No 5    Stuedal et al.
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such as fibroblasts [56], and thereby cause stromal alterations
reflected by increased mammographic density [57].
Because the level of leptin in breast fat might be biologically
important, it seems probable that plasma levels as a marker for
breast level leptin are only comparable in women with the
same amount of breast adipose tissue – or, in other words,
that breast adipose tissue may be a modifier of the leptin-mam-
mographic density association. We therefore stratified our
analyses on the mammographic nondense area, and a role for
breast fat in modifying the association between leptin and
mammographic density was suggested (P for interaction =
0.05).
It is possible that, with increasing breast fat, locally secreted
leptin would exert most influence on the breast epithelial/stro-
mal tissue, and plasma leptin would be less important. This
could be a biological explanation for our finding that the mam-
mographic density increased significantly across quartiles of
plasma leptin levels in the medium stratum of breast fat,
whereas this increase was not found in the upper stratum. If
plasma leptin is associated with increased mammographic
density in breasts only containing a modest amount of fat,
however, we would expect the strongest association between
plasma leptin concentration and mammographic density in the
first stratum of breast fat. This is not what we found, indicating
that our results may be due to chance.
There is some evidence for an association between estrogen
and leptin, but the direction of this association is not clear.
Estrogens have been shown by some investigators [58], but
not all [59], to stimulate leptin production from female omental
adipose tissue in vitro. Furthermore, it is unclear whether
plasma leptin levels are affected by endogenous estrogens
[60,61], by menopause or by the use of hormone replacement
therapy [62]. In the present study, leptin levels did not differ
with the use of postmenopausal hormone therapy, and neither
was the association between plasma leptin concentration and
mammographic density modified by hormone use (categorized
as current use/non-current use; P for interaction = 0.23). We
were unable to adjust for endogenous estrogen levels, but we
adjusted for obesity, the major determinant of estrogen levels
in postmenopausal women [63]. Leptin has been shown to
stimulate the action of the aromatase enzyme in some women
[64]. If estrogens mediate the effect of leptin on mammo-
graphic density, this would make estrogens an intermediate
step in the association between leptin and mammographic
density in our analyses, and should as such not be adjusted
for.
The strengths of our study are the large sample size, and that
it was a part of a population-based screening project with a
high attendance rate. The reader of the mammograms was
experienced, and was blinded to the characteristics of the
women.
Limitations of our study include potential misclassification of
plasma leptin levels because the participants were nonfasting
[65] and their blood samples were not drawn at the same time
of the day [66]. Some misclassification could arise because
leptin was measured only once, although single measure-
ments of circulating leptin appear to reflect long-term levels
rather well [67,68]. These misclassifications would most prob-
ably bias our results towards the null. In the stratified analyses,
the low number of women in some of the leptin quartiles limits
the interpretation of our findings.
The BMI as a measure of body fat is not accurate [69], and
there could be a residual confounding effect by body fat on the
association between leptin concentration and mammographic
density. This would tend to obscure a positive association.
Furthermore, the estimation of breast fat using the nondense
component on the mammogram, a two-dimensional picture, is
a crude approximation of the volume of mammary adipose tis-
sue. A study that estimated breast adipose tissue based on
magnetic resonance imaging found that mammograms gave
an especially poor estimate among women with dense breasts
[70]. It is thus possible that we have misclassified the amount
of fat among women with dense breasts, and we could there-
fore have some misclassification of the stratification variable.
Leptin was the only adipocytokine measured in the present
study. However, several other fat-secreted substances have
been suggested to provide links between obesity and breast
cancer, such as adiponectin [71], hepatocyte growth factor
[72] and IL-6 [7], perhaps through interfering with insulin
resistance and estrogen synthesis [73]. The association of
these substances with mammographic density is to our knowl-
edge not known.
Conclusion
Our results do not support a growth-stimulating effect of
plasma leptin on mammographic density. Although weak and
possibly due to chance, we found some evidence that breast
fat may modify the association between the leptin concentra-
tion and mammographic density.
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